Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study

Anti-cancer drugs

Volumn 25, Issue 9, 2014, Pages 1095-1101

  Joka, Mareile ^a   Boeck, Stefan ^a   Zech, Christoph J ^a   Seufferlein, Thomas ^a   Wichert, Goetz von ^a   Licht, Thomas ^a   Krause, Annekatrin ^a   Jauch, Karl Walter ^a   Heinemann, Volker ^a   Bruns, Christiane J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EVEROLIMUS; GEMCITABINE; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; VASCULARIZATION; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS; PANCREATIC NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 85027932513     PISSN: None     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000146     Document Type: Article

References (0)